Videos

AACR data suggest 60% of early-onset cancers could be found with existing tests, prompting calls for earlier, risk-based screening.

Trial data guide EGFR lung cancer first-line choices: amivantamab+lazertinib may edge osimertinib+chemo, especially with TP53 mutations.

This episode focuses on practical decision-making for selecting among HER2-directed therapies after progression on chemo-immunotherapy.

Compare EGFR lung cancer first-line options—osimertinib, amivantamab/lazertinib, or chemo combo—balancing visits, survival, and risks.

This episode examines second-line therapy selection when brain metastases are present in HER2-mutant non-small cell lung cancer.

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or chronic graft-vs-host disease.

Dr Roberto Borea explores how BMI impacts NSCLC survival and molecular pathways, revealing key T-cell and redox data for IO and TKI treatment cohorts.

Zongertinib shows 77% frontline responses and 96% disease control, with rapid onset and promising durability versus other HER2 TKIs.

In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in community practice and how these factors influence treatment selection. Dr. Wulff and Dr. Geynisman discuss practical strategies for adapting guideline-based therapies in patients with cardiovascular disease, pulmonary conditions, and baseline anemia.

In this segment on advanced renal cell carcinoma, Dr. Geynisman discusses how clinicians decide between single-agent TKIs and combination approaches in later-line treatment settings.

FDA‑approved zongertinib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving hematopoietic cell transplant.

Dr. Alexander B. Olawaiye speaks on how the ROSELLA trial shows relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer.

An ongoing trial could establish new standard of care for chronic graft-vs-host disease.

Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.

Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.

Persistent itch can signal serious immunotherapy skin toxicity; learn triage tips, risk factors, and when to refer to dermatology fast.

Amandeep Salhotra, MD, discusses a retrospective observational analysis comparing Orca-T to standard graft with posttransplant cyclophosphamide.

Dr. Doroshow addresses the critical gap that shaped Sandra's treatment trajectory: incomplete upfront molecular testing in community oncology.

Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.

Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss over 2 months.

Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung cancer (NSCLC), adenocarcinoma subtype.

The ACCESS study of post-transplant cyclophosphamide in stem cell transplant showed that even 6/8 and 5/8 HLA matches can be considered as donors.

Explore why high‑risk CLL often favors continuous BTK inhibitors over time‑limited venetoclax, balancing efficacy with clinic-visit burden.

Long-term zanubrutinib keeps atrial fibrillation risk low while manageable hypertension, neutropenia and infections emerge with continued therapy.

High‑risk del17p CLL patients on single‑agent zanubrutinib show durable progression‑free survival, rivaling outcomes in standard‑risk groups.

High-risk DEL17p CLL patients show durable progression-free survival on single-agent zanubrutinib, matching outcomes seen in standard-risk groups.

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk del17p/TP53 patients.

Longer follow-up of patients receiving a modern prophylactic regimen shows positive outcomes for preventing chronic GVHD and relapse after stem cell transplant.

New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.